An association between HIV infection, antiretroviral therapy (ART), and coronary heart disease (CHD) has been reported in several studies in recent years (1) (2) (3) (4) . HIV infection has become a chronic disease in countries in which effective combination ART (cART) has been available since the mid-1990s. Over the same period, an increasing number of reports have been published on the occurrence of acute coronary syndromes (ACS) in this population, in those age Ͻ50 years. This article discusses the current understanding of the interaction between HIV infection, immune activation, antiretroviral drugs, conventional risk factors, and CHD. Several key areas of importance to cardiologists in the management of patients with HIV infection and CHD are addressed:
• Is CHD more prevalent, and does it occur prematurely, in the HIV population compared to the general population? • Does cART affect the risk for CHD?
• Is the pathophysiology of CHD in the HIV-infected population similar to that in the general population? • What are the clinical and angiographic presentations of CHD in the HIV-infected population? • Is the prognosis of CHD different in HIV-infected patients?
• Can CHD be prevented in patients infected with HIV?
Epidemiology
As a consequence of cART, the spectrum of diseases related to HIV has shifted in Western countries from opportunistic AIDS-related diseases toward long-term age-related complications, including cardiometabolic alterations and cancers.
Recent reports have shown that cardiovascular deaths accounted for 6.5% of total deaths in a large observational cohort of HIVinfected patients from Europe and North America, for 8% of deaths among HIV-infected people in France, and for 15% of deaths in a North American HIV outpatient study (5) (6) (7) . Prevalence and incidence of CHD. Data from 2 observational studies show that, compared to the general population, HIV-infected patients have a higher rate of CHD (defined as myocardial infarction [MI] ) (2, 8) . In the French Hospital Database on HIV (FHDH), compared to the general population and irrespective of age class, the standardized mortality ratio was 1.5 in HIV-infected men and women (1.4 for men and 2.7 for women) (2) , and in a North American cohort, the risk ratio was 1.7 (8) . In several cohorts from published studies, the mean age at which MI occurred in HIV-infected patients was around 48 years, far less than that reported in the general population. However, the median age of the HIV population is also far less than that of the general population, leading to a younger age at diagnosis of MI. This prematurity, if any, could be due to an acceleration of atherosclerosis by HIV and/or an earlier exposure to conventional cardiovascular risk factors. Impact of cART on CHD. Although it is now clearly established that cART is linked to metabolic disorders, the long-term impact of these conditions remains the subject of discussion. cART is currently defined as any combination of 3 antiretroviral drugs, usually 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), or a non-nucleoside reverse transcriptase inhibitor (NNRTI) and an integrase inhibitor. The first signs of an increased risk for CHD possibly related to PIs appeared in 1998, with the publication of reports of MI occurring in young HIVinfected patients treated with PIs and associated with raised concentrations of cholesterol (9 -12) . Thereafter, some (3, (13) (14) (15) (16) (17) (18) (19) (20) , but not all (21) (22) (23) , studies have shown a link between the risk for CHD and exposure to PIs (Table 1) . Although a number of these studies had methodologic limitations, the 2 most important and recent observational cohorts (3, 20) with a sufficient duration of exposure to PIs showed that the duration of exposure was associated with an increased risk for MI. This was the case for cumulative exposure to any PI (except for saquinavir) (odds ratio: (20) . No conclusive data are available on atazanavir or darunavir. After adjustment for lipid concentrations, the impact of these PIs (indinavir, lopinavir, ritonavir) remained significant. This finding may support the direct impact of PIs, independent of lipid-induced abnormalities, on the risk for MI. Moreover, the rate of MI associated with PI exposure changed little, regardless of whether the effects of PIs were boosted with ritonavir (3, 20) . However, the PI risk-benefits ratio remains positive, as the increase in life expectancy conferred by cART far outweighs the associated risk for MI. Law et al. (24) calculated that the 3-year risk for MI increased from 0.30% (95% CI: 0.20% to 0.38%) in antiretroviral-naive patients to 1.07% (95% CI: 0.43% to 1.77%) in patients receiving antiretroviral agents from all 3 classes. In this publication, the estimated 3-year risk for AIDS or death was between 6.2% and 11.1% among ART-treated patients staying on treatment, rising to between 22.5% and 29.4% when they ceased taking ART. Neither the FHDH nor the D:A:D study found any significant association between the development of MI and cumulative exposure to an NNRTI (efavirenz or nevirapine).
Regarding NRTIs, the D:A:D study (20) found an association between cumulative and recent exposure to abacavir and an increased risk for MI (RR [95% CI]: 1.07 [1.00 to 1.14] and 1.70 [1.17 to 2.47], respectively), whereas the FHDH study (3) did not find any causal relationship because the observed association with short-term or recent exposure to abacavir was unstable in sensitivity analyses. Recent exposure to didanosine was associated with an increased risk for MI in the D:A:D study (RR: 1.41; 95% CI: 1.09 to 1.82), but not in the FHDH study. Three meta-analyses (25) (26) (27) and a retrospective study from the Veterans' cohort (28) showed no significant association between abacavir use and MI. In contrast, a retrospective study nested in the Canadian public health insurance database showed an increased risk for MI in the HIV population compared with the general population, and that exposure to abacavir was associated with an increased risk for MI (29) . These differences can be explained by the presence of confounding factors, such as smoking, kidney function, cocaine and/or intravenous drug use, and potential selection biases. Therefore, at present it is not possible to draw any conclusions regarding a causal relationship between treatment with abacavir and the risk for developing MI (30) .
Cardiovascular Risk Factors
Patients infected with HIV are at higher calculated risk for CHD compared with the general population of the same age (31, 32) . Typically, compared with age-related controls, HIV-infected patients exhibit higher rates of conventional risk factors such as smoking (32) , dyslipidemia (31,33), hypertension (34, 35) , and insulin resistance or diabetes mellitus (16, (33) (34) 36) . Conventional cardiovascular risk equations do not take into account emerging cardiovascular risk factors such as inflammation (37, 38) , immune activation (39 -41) , coagulation disorders (42, 43) , kidney disease (44) , HIV itself (45) , and cART that have been associated with the increased risk of MI or atherosclerosis in HIVinfected patients. Cocaine use, may increase the risk for ACS, is relatively common among HIV-infected patients, particularly in North America, and consumption is increasing in Europe (46) . Renal function and albuminuria have also been strongly associated with the risk for MI in HIV-infected patients (44) . All of these cardiovascular risk factors are interconnected and synergistic, leading to difficulties in analyzing the specific role of each, particularly the impact of HIV itself and of cART. Recently, the D:A:D study group developed a risk-assessment tool tailored to HIV-infected patients and incorporating exposure to PIs and NRTIs (47) .
Importantly, cardiovascular risk should also be evaluated in HIV-infected children because vertically infected individuals have been exposed long-term to both HIV and cART. A risk for cardiomyopathy has been described in HIV-infected children exposed to HIV and/or cART from HIV-infected mothers, and in uninfected children of HIVinfected mothers exposed to ART (48 -50) . The presence of dyslipidemia, chronic inflammation, and subclinical atherosclerosis has been reported in HIV-infected children (51, 52) . Indeed, a recent study using magnetic resonance angiography suggested possible early coronary atherosclerosis in HIV-infected children (53) . Moreover, the risk for premature atherosclerosis in adulthood among HIVinfected children requires further investigation to develop accurate strategies of prevention.
Pathophysiology
The pathophysiology of CHD in HIV-infected patients is complex, combining both conventional vascular risk factors and emerging risk factors. The effects of HIV infection in cART-naive patients and in cART-treated patients should be considered separately. Many factors associated with the risk for CAD in HIV-infected patients have been determined in several studies by association or indirectly and therefore lead to hypothetic and speculative explanation for the moment. HIV infection and risk for CHD in treatment-naive patients. Recently, Baker and Lundgren (4) reviewed the potential impact of HIV infection on the cardiovascular system in untreated HIV-infected patients. They suggested that HIV infection could promote atherosclerosis through mechanisms related to immune activation, chronic inflammation, coagulation disorders, and/or lipid disturbances (Fig. 1) . The SMART (Strategies for Management of Antiretroviral Therapy) study (45) was designed to assess an HIV treatment strategy of continuous compared with episodic ART guided by CD4 ϩ count. That study indirectly highlighted the role of HIV replication and dysimmunity after the cessation of ART in the increased risk for MI. In fact, in the patients on episodic ART, the risk for major cardiovascular events was greater than in the group on continuous therapy (hazard ratio [HR] for major cardiovascular, renal, or hepatic disease: 1.7 [95% CI: 1.1 to 2.5; p ϭ 0.009]; HR for fatal or nonfatal cardiovascular disease: 1.6 [95% CI: 1.0 to 2.5; p ϭ 0.05]).
Enhanced endothelial injury ( Fig. 1 ) due to adhesion molecules (54) , HIV Tat protein, and related angiogenic effects (55) has been shown. Direct HIV infection could also stimulate proliferation of human vascular smooth muscle cells and therefore promote atherosclerosis (56) . HIV infection could lead to coagulation disorders (a "prothrombic state") associated with increased concentrations of D dimers, fibrinogen, factor VII, von Willebrand and tissue factors, and abnormal platelet reactivity (43, 55) . Finally, HIV alone, independent of cART, is associated with known atherogenic dyslipidemia associated with increased concentrations of triglycerides (impaired lipase activity) and decreased concentrations of high-density lipoprotein cholesterol correlated with a higher concentration of cytokines (57) . Antiretroviral agents and risk for CHD. In cARTtreated HIV-infected patients, immune activation and lowgrade chronic inflammation may promote atherosclerosis ( Fig. 1 ). Whether the inflammatory balance and/or immune activation participates in atherosclerosis acceleration remains debated and speculated (39, 58) . However, the roles played by chronic immune activation and inflammation in HIV pathogenesis have become increasingly apparent and are associated with pathologies linked with aging and so-called "inflammaging," such as bone demineralization, CHD, cancer, and immune senescence (59) . Chronic inflammation has been associated with an increased risk for death (37, 60, 61) . Immune activation can promote atherosclerosis and increased arterial stiffness in the absence of residual viral replication (62) (63) (64) (65) (66) . Whether the control of immune activation could decrease accelerated atherosclerosis in HIV-infected patients remains to be determined. Finally, increased intestinal bacterial translocation associated with immune activation and its impact on atherosclerosis warrants further investigation (67) .
Whether cART, and in particular PIs, increases the risk for CHD has been extensively debated over the past decade (68,69) (see previous discussion). The impact of cART on lipid and glucose metabolism via adipocyte dysfunction leading to a lipodystrophy syndrome ( Fig. 1 ) has been demonstrated both in vitro and in vivo in HIV-infected patients (33, 36, 70) . The potential metabolic effects and proatherogenic effects of each class of antiretroviral agents are depicted in Table 2 (data should be interpreted with caution because the metabolic impact of these different drugs has not been compared directly). These effects vary from one drug to another, and are associated with other risk factors such as environmental and genetic factors (71 effects of PIs on high-density lipoprotein cholesterol concentrations, together with the proper effect of HIV itself on this lipoprotein, seem to play a crucial role in the increased risk for CHD in the HIV population, which is much higher than that related to the rise in triglyceride concentrations typically found in this context (72, 73) . PI-induced endothelial injury has been associated with dyslipidemia, oxidative stress, and senescence (74) . In contrast, the AIDS Clinical Trials Group 5152 study showed that cART improved endothelial dysfunction in treatment-naive HIV-infected patients after 24 weeks of therapy (75) . Therefore, the short-term and long-term adverse events with PIs may have a different impact on the risk for CHD. Recently, similar molecular pathophysiological mechanisms have been observed in cells from patients with the Hutchinson-Gilford syndrome (progeria) and treated with PIs in vitro (74, 76) . In fact, progeria is associated with premature aging and early CHD caused by the accumulation of progerin (truncated prelamin A). Aging of vascular smooth muscle cells is associated with the accumulation of prelamin A, leading to premature senescence (76) . Importantly, some PIs boosted with ritonavir induce in vitro senescence of human fibroblast and endothelial cells as the result of prelamin A accumulation (74) . Therefore, the authors speculate that premature aging and early CHD in HIV-infected patients could be partly caused by the acquired prelamin A accumulation.
Clinical Presentation
The spectrum of CHD in HIV-infected patients is similar to that in non-HIV-infected patients, with various clinical presentations including silent ischemia, stable angina, and ACS (unstable angina, non-ST-elevation MI and predominant ST-elevation MI). In HIV-infected patients, the presence of CHD is usually revealed by the occurrence of ACS. In published studies on ACS in HIV-infected patients (Table 3 ) (21, (77) (78) (79) (80) (81) (82) , the typical patient is a young man (Ͻ50 years of age in Ͼ90% of cases) with a long known duration (Ͼ8 years) of HIV disease (however, this criterion is not accurate, as the duration of HIV seropositivity does not represent the duration of HIV infection, and therefore the nadir CD4 cell count could be used) who is taking cART (53% to 96%), generally including a PI (Ͼ59%); is a smoker (Ͼ45%); and is dyslipidemic (17% to 58%). In these studies, the most frequent presentation is ST-segment elevation MI (29% to 64%), followed by non-ST-segment elevation MI (20% to 48%) and unstable angina (18% to 46%). Men are affected predominantly, as in the general population, representing between 81% and 97% of the cohorts (21, (77) (78) (79) (80) (81) (82) . Studies on frequency, causes, and determinants of sudden death in HIV-infected patients are lacking. One mechanism of sudden death could be PI-induced ventricular fibrillation. In fact, whether HIV PIs induce QT prolongation is being discussed, but if this is the case, the impact does not appear to be clinically relevant (83,84). 
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Angiographic Features
The coronary angiographic features of CHD in HIVinfected patients have been reported in a number of studies that varied in terms of their design (cohort, case control, cross-sectional) and number of patients enrolled (16 to 103) ( p ϭ 0.007). However, the control group was not matched for age with the HIV-infected group. In the other studies (80, 82, 86, 87) with the specific angiographic comparison predefined and with age-matched control patients, no differences were found (Table 4 ). The primary method of revascularization reported in these publications on ACS is percutaneous coronary intervention (PCI) (25% to 76%), followed by coronary artery bypass grafting (CABG) (4% to 18%) and medical therapy alone (10% to 20%).
Prognosis With ACS and Coronary Revascularization
The prognosis of HIV-infected patients during the acute phase of ACS has been evaluated in a few studies (78 -80,82) . The in-hospital mortality rate varied from 0% to 8%, and no differences in terms of heart failure and Antiretroviral therapy and HIV itself could promote coronary heart disease (CHD) along with environmental and genetic factors. Adipose tissue and liver dysfunction have been associated with the accumulation of visceral fat, epicardial fat, and liver steatosis leading to metabolic disturbances (decreased adiponectin and glucose uptake, insulin resistance, dyslipidemia, and increased in situ and systemic inflammation). Both HIV and combined antiretroviral therapy (cART) have a deleterious impact on adipose tissue. Residual HIV replication even under potent cART, and reactivation of other viruses (e.g., cytomegalovirus [CMV]) could lead to permanent immune activation and to a degree of immune senescence that could favor atherosclerosis. Chronic inflammation could persist under cART potentially due to increased microbial translocation in the gut, associated with coagulation disorders. Adipose tissue dysfunction, immune activation, and chronic inflammation could result in vascular and endothelial dysfunction, leading to atherosclerosis and acute ischemic events. ART ϭ antiretroviral therapy; CRP ϭ C-reactive protein; F VII ϭ factor VII; FFA ϭ free fatty acids; HDLc ϭ high-density lipoprotein cholesterol; IL6 ϭ interleukin 6; NO ϭ nitrogen oxide; PAI-1 ϭ plasminogen activator inhibitor type 1; PPAR ϭ peroxisome proliferatoractivated receptors; RAS ϭ Renin angiotensin system; ROS ϭ reactive oxygen species; sCD14 ϭ soluble CD14; TG ϭ triglyceride; TNF ϭ tumor necrosis factor; VSMC ϭ vascular smooth muscle cells. CABG ϭ coronary artery bypass grafting; DES ϭ drug-eluting stent; LAD ϭ left anterior descending; LCA ϭ left circumflex artery; LMD ϭ left main disease; Med ϭ medical therapy alone; ND ϭ not documented; NR ϭ not reported; NSS ϭ not significant stenosis; PCI ϭ percutaneous coronary intervention; RCA ϭ right coronary artery; VD ϭ vessel disease; other abbreviations as in Table I. reinfarction were found when a control group was included (80, 82) . However, when long-term follow-up was performed, HIV-infected patients exhibited a higher rate of recurrent ischemic events compared with controls, but long-term cardiovascular and total mortality did not differ (80, 82) . In the PACS (Prognosis of Acute Coronary Syndrome in HIV-Infected Patients) study (82) , recurrent ACS was more frequent in HIV-infected patients compared to uninfected patients (HR: 6.5; 95% CI: 1.7 to 23.9). After 3 years of follow-up in this cohort, HIV status and lipid parameters were the only independent predictors of recurrent ACS (88) .
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Regarding the prognosis of patients undergoing PCI, the initial high rate of procedural success appears similar to that in the general population. Rates of acute and late stent thrombosis are low (between 1% and 4%) and did not differ between HIV-infected and uninfected patients in 2 studies that looked specifically at this endpoint, but these studies were not powered to detect such a difference (82, 87) . The rate of clinical restenosis has been evaluated in a few studies (77,80 -82,87) , varying from 9% to 52%, and did not differ from that in controls in the stenting group (81, 82, 87) . Ren et al. (87) -in a single-center study in California-compared the rate of clinical restenosis between HIV-infected and uninfected patients undergoing PCI with bare-metal stents or drug-eluting stents. The investigators found that drugeluting stents decreased the rate of major adverse cardiac events (MACE) in both groups by around 60% compared to the HIV-uninfected patients who received bare-metal stents after a 3-year follow-up, without an increased rate of stent thrombosis. They concluded that drug-eluting stents are as safe and as efficacious in the HIV-infected population as in the general population. In addition, in both the study by Ren et al. (87) Recently, a meta-analysis showed that HIV-infected patients with ACS had a significant long-term risk for recurrent coronary revascularization and MI (89) .
Concerning CABG, only a few studies (90 -93) have included HIV-infected patients (Table 5 ). These studies showed that the immediate and postoperative periods after CABG are uneventful and do not differ from those in non-HIV-infected patients. At long-term follow-up, there was no difference in rate of cardiovascular death. CABG had no immunosuppressive effects and did not worsen the prognosis of patients with HIV disease. Regarding heart transplantation in HIV-infected patients with severe left ventricular dysfunction, few data are available (94, 95) , but HIV itself is not a contraindication, but the authors recommend case-by-case discussions between HIV physicians and cardiologists.
Prevention and Treatment
Cardiovascular risk stratification in HIV-infected patients needs to be evaluated before starting and during treatment with cART. Reducing risk factors should become routine in the care of HIV-infected patients, who now live longer. Intervention studies aimed at reducing cardiovascular risk in HIV-infected patients are now warranted (e.g., smoking cessation, increased physical activity, use of lipid-lowering drugs and aspirin).
Guidelines on cardiovascular risk reduction in HIVinfected patients have been published and generally follow those for the general population (96 -98) . It is important to highlight the treatment of atherogenic dyslipidemia frequently found in HIV-infected patients taking cART. Serum concentrations of lipids, particularly triglycerides, should be evaluated in the fasting patient before cART is started, at 3 to 6 months after initiation, and then yearly in the absence of abnormalities. National Cholesterol Education Program III guidelines should be applied to HIVinfected patients, as suggested by other guidelines for the management of dyslipidemia in HIV-infected patients (96) (97) (98) (99) . Lipid-lowering therapy should be prescribed with caution in HIV-infected patients because of the potentially severe interaction between statins and fibrates, as well as PIs (Table 6 ). Several statins are metabolized via the cytochrome P450 (CYP) 3A4 pathway. PIs and ritonavir mainly inhibit CYP and could increase the toxicity of some statins (Table 6 ). NNRTIs (e.g., efavirenz) are inducers of CYP and could reduce statin efficacy. In the HIV-infected patient taking a PI, if a statin is prescribed (e.g., for primary or secondary prevention in the high-risk patient), the preferable choice is pravastatin, fluvastatin, low-dose atorvastatin, or low-dose rosuvastatin, as these statins have a low risk for interaction with PIs (99 -101). Pitavastatin-a new statin not metabolized by the CYP 3A4 isozyme and primarily excreted unchanged in the bile with little renal elimination-has not been evaluated in this context but could present a therapeutic option; this statin has not, however, shown any clinical benefit in randomized trials (102) . Whether a PI should be switched to an NNRTI or to a new drug such as integrase or chemokine (C-C motif) receptor 5 (CCR5) inhibitors when dyslipidemia is present, to avoid adjunctive therapy with a statin, is debatable. In fact, physicians treating HIV-infected patients have several therapeutic options in this context: to continue PI therapy and add a statin or to switch the PI to an NNRTI or a novel drug such as an integrase inhibitor. No trials comparing the 2 strategies in terms of cardiovascular prevention have been performed. The impact on lipids of switching from firstgeneration NRTIs to second-generation NRTIs is low (as they are less proatherogenic), and the associated beneficial impact on CHD is unknown. Fibrates should be prescribed when the triglyceride concentration is above 500 mg/dL (96 -98) . In this case, the measurements of non-highdensity lipoprotein cholesterol, apolipoprotein B, or both may be useful because low-density lipoprotein cholesterol measurement may underestimate the true CHD risk, especially in lipodystrophic patients. Ezetimibe may be useful and well tolerated in achieving the low-density lipoprotein goal in association with a statin (103), as HIV-infected patients are susceptible to muscular pain before statin prescription. However, no clinical benefit of ezetimibe has been shown in the general population except for patients with chronic kidney disease in primary prevention (104) . The risk-benefits ratio of treating HIV-infected patients with dyslipidemia is unknown. Male patients age Ͼ45
years and female patients Ͼ55 years with hypertension and/or diabetes and/or familial premature CHD are candidates for lipid-lowering therapy. In secondary prevention, whether PI therapy should be discontinued after an ACS and cART switched, if virologically possible, to a drug class with a better "atherogenic profile," needs further investigation. Finally, statins as potent lipidlowering drugs and major agents in primary and secondary cardiovascular prevention, along with their properties to reverse PI-related senescence of cells and accumulation of prelamin A in vitro (74) and inflammation in vivo (105), need to be tested in a large study of primary prevention in HIV-infected patients. Regarding hypertension, blockers of the renin angiotensin system should be the first therapy because of their protective effects on the vasculature, on glucose metabolism and kidney function (44, 70) .
The prescription of antiplatelet drugs such as aspirin, clopidogrel, prasugrel, and ticagrelor should follow the guidelines for the general population (106) . In primary prevention, aspirin should be given if the level of CHD risk is high and in the absence of contraindications (107) . Recently, questions have been raised about platelet function and activity in HIV-infected patients (42, 108) . A potential interaction between the most commonly prescribed PI (ritonavir) and prasugrel has been found recently (by decreasing its activity) in vitro (109) . Ticagrelor is metabolized by CYP 3A4/5 and should not be prescribed in HIV-infected patients undergoing PI therapy, particularly ritonavir (a potent inhibitor of this CYP isozyme) (110) . Studies on antiplatelet "resistance" in HIVinfected patients need to be performed urgently. However, the rate of stent thrombosis after PCI does not appear to be higher in the HIV population than in the non-HIV-infected patients (82, 87) .
